Invivoscribe Advances Molecular Clonality Testing Portfolio with a Comprehensive LymphoTrack® Flex Suite 2026-10-06T03:43:09-07:00October 6th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Begins Commercial Shipments of PrepQuantTM Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing 2026-09-02T12:39:37-07:00September 2nd, 2026|2026 Press Releases, Press Releases| Read more
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care 2026-11-05T09:24:45-08:00August 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Announces the PrepQuantTM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows 2026-10-06T14:42:21-07:00April 15th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification 2026-03-25T23:07:06-07:00March 25th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Launches LeukoStrat KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide 2026-10-06T14:42:59-07:00February 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Advances Molecular Clonality Testing Portfolio with a Comprehensive LymphoTrack® Flex Suite 2026-10-06T03:43:09-07:00October 6th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Begins Commercial Shipments of PrepQuantTM Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing 2026-09-02T12:39:37-07:00September 2nd, 2026|2026 Press Releases, Press Releases| Read more
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care 2026-11-05T09:24:45-08:00August 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Announces the PrepQuantTM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows 2026-10-06T14:42:21-07:00April 15th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification 2026-03-25T23:07:06-07:00March 25th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Launches LeukoStrat KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide 2026-10-06T14:42:59-07:00February 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial 2026-03-09T18:04:28-07:00July 7th, 2025|2025 Press Releases, Press Releases| Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials 2026-03-09T18:40:09-07:00June 17th, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay 2026-03-09T18:44:44-07:00April 22nd, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland 2026-03-09T18:48:48-07:00March 27th, 2025|2025 Press Releases, Press Releases| Read more
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA 2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML 2026-03-09T18:43:04-07:00May 8th, 2024|2024 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA 2025-08-26T07:35:25-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research 2025-12-19T18:08:11-08:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan 2025-12-29T12:29:29-08:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay 2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China 2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan) 2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML 2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML 2026-03-08T22:24:18-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine 2025-08-26T08:08:16-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use 2026-10-16T22:01:40-07:00September 2nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China 2021-07-22T17:27:56-07:00July 22nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System 2025-08-26T08:18:25-07:00June 24th, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China 2026-10-16T21:59:43-07:00June 3rd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States 2025-08-26T08:11:34-07:00May 19th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners. 2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay 2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases| Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA 2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies 2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco 2026-10-21T19:22:10-07:00January 3rd, 2019|2019 Press Releases, Press Releases| Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japan 2021-02-26T19:11:02-08:00November 29th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib 2026-10-26T12:38:02-07:00November 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan 2026-10-26T12:15:59-07:00November 19th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate) 2026-10-26T12:32:28-07:00September 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels 2021-02-26T19:12:15-08:00May 9th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations 2021-02-26T19:12:23-08:00May 8th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software 2026-10-21T19:23:02-07:00November 7th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit. 2026-10-21T19:20:01-07:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
FDA approves new combination treatment for acute myeloid leukemia 2021-02-26T19:12:55-08:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML 2026-10-26T12:21:04-07:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies 2026-10-21T21:31:07-07:00March 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software 2021-02-26T19:13:58-08:00February 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits 2021-02-26T19:14:04-08:00February 14th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits 2021-02-26T19:14:11-08:00January 31st, 2017|2017 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis 2021-02-26T19:14:23-08:00November 14th, 2016|2016 Press Releases, Press Releases| Read more
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development 2021-02-26T19:14:30-08:00May 31st, 2016|2016 Press Releases, Press Releases| Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position 2026-10-26T12:22:46-07:00March 28th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) 2021-02-26T19:14:49-08:00February 18th, 2016|2016 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific 2026-10-21T19:23:59-07:00February 9th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations 2021-02-26T19:16:48-08:00December 5th, 2015|Archived Press Releases, Press Releases| Read more
Invivoscribe Advances Molecular Clonality Testing Portfolio with a Comprehensive LymphoTrack® Flex Suite 2026-10-06T03:43:09-07:00October 6th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Begins Commercial Shipments of PrepQuantTM Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing 2026-09-02T12:39:37-07:00September 2nd, 2026|2026 Press Releases, Press Releases| Read more
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care 2026-11-05T09:24:45-08:00August 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Announces the PrepQuantTM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows 2026-10-06T14:42:21-07:00April 15th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification 2026-03-25T23:07:06-07:00March 25th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Launches LeukoStrat KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide 2026-10-06T14:42:59-07:00February 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial 2026-03-09T18:04:28-07:00July 7th, 2025|2025 Press Releases, Press Releases| Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials 2026-03-09T18:40:09-07:00June 17th, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay 2026-03-09T18:44:44-07:00April 22nd, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland 2026-03-09T18:48:48-07:00March 27th, 2025|2025 Press Releases, Press Releases| Read more
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA 2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML 2026-03-09T18:43:04-07:00May 8th, 2024|2024 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA 2025-08-26T07:35:25-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research 2025-12-19T18:08:11-08:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan 2025-12-29T12:29:29-08:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay 2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China 2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan) 2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML 2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML 2026-03-08T22:24:18-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine 2025-08-26T08:08:16-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use 2026-10-16T22:01:40-07:00September 2nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China 2021-07-22T17:27:56-07:00July 22nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System 2025-08-26T08:18:25-07:00June 24th, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China 2026-10-16T21:59:43-07:00June 3rd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States 2025-08-26T08:11:34-07:00May 19th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners. 2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay 2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases| Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA 2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies 2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco 2026-10-21T19:22:10-07:00January 3rd, 2019|2019 Press Releases, Press Releases| Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japan 2021-02-26T19:11:02-08:00November 29th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib 2026-10-26T12:38:02-07:00November 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan 2026-10-26T12:15:59-07:00November 19th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate) 2026-10-26T12:32:28-07:00September 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels 2021-02-26T19:12:15-08:00May 9th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations 2021-02-26T19:12:23-08:00May 8th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software 2026-10-21T19:23:02-07:00November 7th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit. 2026-10-21T19:20:01-07:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
FDA approves new combination treatment for acute myeloid leukemia 2021-02-26T19:12:55-08:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML 2026-10-26T12:21:04-07:00April 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies 2026-10-21T21:31:07-07:00March 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software 2021-02-26T19:13:58-08:00February 28th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits 2021-02-26T19:14:04-08:00February 14th, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits 2021-02-26T19:14:11-08:00January 31st, 2017|2017 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis 2021-02-26T19:14:23-08:00November 14th, 2016|2016 Press Releases, Press Releases| Read more
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development 2021-02-26T19:14:30-08:00May 31st, 2016|2016 Press Releases, Press Releases| Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position 2026-10-26T12:22:46-07:00March 28th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) 2021-02-26T19:14:49-08:00February 18th, 2016|2016 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific 2026-10-21T19:23:59-07:00February 9th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations 2021-02-26T19:16:48-08:00December 5th, 2015|Archived Press Releases, Press Releases| Read more
